| Title |
Coronary sinus reducer for the treatment of refractory angina: a literature review |
| Authors |
Kazokas, Domas ; Valiulytė, Linda ; Valiulis, Algirdas ; Kraujutaitytė, Saulė |
| DOI |
10.53453/ms.2025.11.5 |
| Full Text |
|
| Is Part of |
Medicinos mokslai = Journal of medical sciences.. Kėdainiai : VšĮ Lietuvos sveikatos mokslinių tyrimų centras. 2025, vol. 13, iss. 5, p. 48-60.. ISSN 2345-0592 |
| Keywords [eng] |
coronary sinus reducer ; coronary sinus reduction ; refractory angina ; non-pharmacological treatment |
| Abstract [eng] |
Background. Refractory angina remains an important health issue despite improvements in coronary artery disease diagnosis and treatment, and its incidence is expected to grow. Although patients with refractory angina exhibit a mortality rate comparable to that of individuals with asymptomatic stable angina, the quality of life is worse and associated healthcare expenditure is higher. After having exhausted all treatment options, coronary sinus reducer (CSR) has recently gained more attention as a non – pharmacological treatment of refractory angina. Aim. To summarize the current knowledge about CSR for the treatment of refractory angina, its mechanism of action, efficacy, safety and cost-effectiveness. Materials and methods. A comprehensive literature search was performed on PubMed database using the keywords “coronary sinus reduction” AND “refractory angina”, focusing on articles published in English in the last 5 years. Results. Implantation of the CSR creates backward pressure in the coronary venous circulation resulting in a redistribution of flow from the subepicardial to the ischaemic subendocardial region. This translates into sustained angina reduction as demonstrated by a significant improvement in Canadian Cardiovascular Society angina class, quality of life, mainly as assessed by the Seattle Angina Questionnaire, increased exercise tolerance as assessed by the 6-minute walk test and improved left ventricular systolic function. Under proper selection, CSR could also be of benefit to patients with right coronary artery disease. The most common complication is haematoma at the vascular access site. Cost-effectiveness is achieved within 2 years. Conclusions. CSR is an efficient, safe and cost-effective treatment of refractory angina. |
| Published |
Kėdainiai : VšĮ Lietuvos sveikatos mokslinių tyrimų centras |
| Type |
Journal article |
| Language |
English |
| Publication date |
2025 |
| CC license |
|
